Exelixis (EXEL) Change in Accured Expenses (2010 - 2026)
Exelixis (EXEL) posted quarterly Change in Accured Expenses of $4.0 million for Q2 2026, down 12.18% year-over-year from $4.6 million in Q2 2025, and up 1039.15% quarter-over-quarter from $355000.0 in Q1 2026.
Analysis
Exelixis (EXEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Exelixis' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $4.0 million for Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 12.18% year-over-year to $4.0 million; the TTM figure through Apr 2026 stood at $1.3 million (down 83.85% YoY), while the FY2026 annual figure was $1.9 million, up 1374.5% from the prior year.
- Change in Accured Expenses for Q2 2026 stood at $4.0 million, up from $355000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $5.1 million in Q2 2023, with the low at -$54.3 million in Q2 2022.
- The 5-year median for Change in Accured Expenses is $604500.0 (2025), against an average of -$3.4 million.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 5499.1% in 2022, then jumped 223.48% in 2025.
- Exelixis' Change in Accured Expenses stood at -$54.3 million in 2022, then surged by 100.49% to $264000.0 in 2023, then soared by 410.23% to $1.3 million in 2024, then sank by 32.96% to $903000.0 in 2025, then surged by 347.84% to $4.0 million in 2026.
- Business Quant data shows EXEL's Change in Accured Expenses at $4.0 million in Q2 2026, $355000.0 in Q1 2026, and $903000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | -9.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | -9.31 Mn |
| Apr 3, 2026 | 4.04 Mn |
| Jan 2, 2026 | 355,000.00 |
| Oct 3, 2025 | 903,000.00 |
| Jul 4, 2025 | -3.96 Mn |
| Apr 4, 2025 | 4.61 Mn |
| Jan 3, 2025 | 854,000.00 |
| Sep 27, 2024 | 1.35 Mn |
| Jun 28, 2024 | 1.48 Mn |
| Mar 29, 2024 | -3.83 Mn |
| Dec 29, 2023 | 264,000.00 |
| Sep 29, 2023 | -2.19 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | -1.86 Mn |
| Apr 1, 2022 | -54.26 Mn |
| Apr 2, 2021 | 1.01 Mn |
| Jan 1, 2021 | -15.34 Mn |
| Sep 27, 2019 | 23.94 Mn |
| Jun 28, 2019 | -29.17 Mn |
| Mar 29, 2019 | 21.17 Mn |